HD-OPM Archive

Women's heart health, menopause and hormone therapy

How women's heart risk differs from men's, what the group's posts say about menopause, ovarian ageing and hormone therapy (HRT), and which bone, diet and exercise measures matter after menopause.

16 min read48 group posts cited47 studies discussed3 chartsEvidence through Nov 2026AI Summary of posts by Louis Nervegna and Gokhan Can
Key takeaways
  • Men develop cardiovascular disease about 7 years earlier than women on average, and in a Danish CT cohort of 10,003 adults coronary plaque at age 40-44 was found in 6% of women versus 20% of men.
  • Cleveland Clinic guidance shared by Louis says HRT can be reasonably safe for healthy women under 60 or within 10 years of menopause, but risk rises when started more than 10 years after menopause, and women with established cardiovascular disease (10-year ASCVD risk above 10%) or breast cancer should not take it.
  • There is no strong randomized evidence that HRT prevents dementia, and in a 2026 critique of a 183,000-woman cohort the roughly 10% lower dementia diagnosis largely disappeared in women with natural menopause.
  • Statins work as well in women as in men: across 27 trials, major vascular events fell 16% in women versus 22% in men per 1 mmol/L LDL reduction, and all-cause mortality fell 9% versus 10%.
  • Resistance training builds strength at the same rate before and after menopause (126 studies, 4,019 women), while HRT alone does not add muscle.
  • In a 12-month trial of 235 postmenopausal women, 50 g of prunes a day significantly reduced loss of hip bone density compared with no prunes.
In this summary
  1. How women's heart risk differs from men's
  2. Menopause, ovarian ageing and the heart
  3. Hormone therapy: what the group's posts say
  4. Bone health after menopause
  5. Heart-protective measures that work in women
  6. Other women's health topics
  7. What this means for you
  8. Frequently asked questions
  9. The evidence behind this summary

Women's heart risk is not simply a smaller version of men's. On average, women develop cardiovascular disease later, but the gap closes with age, and the way a heart attack happens can differ. Menopause sits in the middle of that story: estrogen falls, weight and metabolic markers often shift, and bone loss speeds up. This summary gathers what the group's posts say about each of these changes, and about the big question many women ask, which is whether hormone replacement therapy (HRT, also called menopausal hormone therapy) helps or harms the heart.

The short version in the group's posts is that HRT is neither a miracle nor a poison. Louis Nervegna, one of the admins, describes it as reasonably safe and beneficial for many women, with clear exceptions: women starting long after menopause, women with established heart disease and women with a history of breast cancer12. He is also openly sceptical of the idea that high levels of sex hormones are "anti-aging"3. Most of the evidence in the posts on HRT and the brain is mixed or negative45.

This article is a summary of discussion in a patient and enthusiast community, not medical advice. The group's admins encourage anyone considering HRT to weigh their own risk profile with their doctor.

~7 yearsearlier onset of cardiovascular disease in men than in women, on average6
10 yearsafter menopause (or age under 60): the window in which HRT may be reasonably safe for healthy women1
16% vs 22%fewer major vascular events per 1 mmol/L LDL drop on statins, women vs men7
50 gof prunes a day slowed hip bone loss over 12 months in postmenopausal women8

How women's heart risk differs from men's

The timing gap

A 2026 JAHA analysis shared by Louis found men develop cardiovascular disease about 7 years earlier than women, driven mostly by earlier coronary heart disease. The difference appears as early as age 35 and persists even after adjusting for traditional risk factors. In the CARDIA cohort, blood pressure and glycemia were among the strongest attenuators of the gap, but did not remove it6.

Cumulative incidence by age in the JAHA analysis (2,327 men and 2,785 women): the male curve pulls away from about age 40 for total cardiovascular disease and coronary heart disease, while stroke curves overlap.
Cumulative incidence by age in the JAHA analysis (2,327 men and 2,785 women): the male curve pulls away from about age 40 for total cardiovascular disease and coronary heart disease, while stroke curves overlap.6

The REACT study in NEJM imaged more than 16,000 adults aged 18-70 without known cardiovascular disease and found plaque in about 57%, rising from 1 in 13 in their 20s to about 9 in 10 in their 60s, with men developing silent disease 5-10 years earlier than women10. Louis uses this to argue that age is by far the biggest risk factor for cardiovascular disease10. In another post he compared hazard ratios from the SCORE O.P. model for people over 65 (using the numbers for women). A hazard ratio of 1.16 per year compounds to about 19.5-fold higher coronary death risk between 65 and 85, compared with 2.3-fold for diabetes and 1.88-fold for smoking11.

Same plaque, different risk?

In a 2026 European Heart Journal Danish cohort of 10,003 asymptomatic adults over 40 who had coronary CT angiography, plaque was less frequent in women at every age: 6% versus 20% at ages 40-44 and 73% versus 92% at ages 75-79. After a median of 6 years, obstructive disease carried a 4.1-fold higher risk of heart attack in women versus 12-fold in men, though the sex interaction was not statistically significant, so the study does not prove that identical plaque is less dangerous in women12.

Women carry less coronary plaque at every ageShare of asymptomatic adults with plaque on coronary CT angiography, Danish cohort of 10,003 adults over 40
WomenMen
Ages 40–446%20%
Ages 75–7973%92%
Source: 12
Show data
WomenMen
Ages 40–446%20%
Ages 75–7973%92%

Heart attacks that do not look like the textbook

A Mayo Clinic study reported that more than half of heart attacks in women under 65 had nontraditional causes, such as spontaneous coronary artery dissection (SCAD) and embolism, rather than classic artery-clogging plaque13.

This matters when interpreting calcium scores. In the Western Denmark Heart Registry (23,759 symptomatic patients, median age 58, 55% women), 54% had a coronary artery calcium (CAC) score of zero, and half of those with symptomatic blockages had a zero score. Louis stresses that a CAC of zero is not a clean bill of health when symptoms are present, particularly in young people and women, because soft plaque can exist before it calcifies141516.

Risk markers studied in women

The Women's Health Study analysis in NEJM followed initially healthy women (mean age 54.7) for 30 years and recorded 3,662 first major cardiovascular events. Comparing the top with the bottom fifth, hazard ratios were 1.70 for hs-CRP (a marker of inflammation), 1.36 for LDL cholesterol and 1.33 for lipoprotein(a). Each contributed independently and a combined measure predicted best, supporting prevention strategies that look beyond 10-year risk estimates17.

Other conditions are flagged as possible risk markers. A Nurses' Health Study analysis of 239,907 women found hysterectomy before age 50 increased cardiovascular risk, with a 21% higher risk in those under 46 who did not use estrogen18. An American Heart Association release on a 10-year study of more than 2.7 million US women found uterine fibroids were linked to more than 80% higher long-term heart disease risk, with the strongest link under age 40. That is observational, and the researchers said more work is needed before changing risk guidelines19.

Menopause, ovarian ageing and the heart

Louis argues that the ovaries are the first organ to age in mammals and that slower ovarian ageing tends to track slower overall ageing and a lower risk of age-related diseases including cardiovascular disease2021. He cites early menopause as a risk factor for heart disease in women20. A shared item suggested women who have their last child after age 33 are more than twice as likely to reach 95, though this is a proposed marker rather than proof of cause21. The shared Pharmacy Times piece suggests anti-Mullerian hormone (AMH) as a possible marker of ovarian function20.

A WebMD item Louis shared reported that postmenopausal women may accumulate atherosclerotic plaque faster than men of the same age, apparently related to loss of estrogen, and that statins alone may not be enough to protect them. No numbers were provided in the post22.

Louis adds a counterweight from comparative biology. A Nature analysis of zoo data found that sterilization and contraception extended lifespan by 10-20% across 117 vertebrate species. He cites this as a reason for suspicion that lifetime exposure to high sex hormones is anti-ageing, because reproduction and longevity appear to trade off3. This is an opinion drawn from animal data, not a statement about HRT in women.

Weight, waist and metabolic health around menopause

In a Nurses' Health Study analysis of more than 38,000 women followed for 12 years around menopause, a low-insulinemic dietary pattern and the Planetary Health Diet were most associated with less weight gain. Women with the highest adherence to the Planetary Health Diet had a 54% lower risk of developing obesity. The common features were more nuts, legumes, fruits, vegetables, whole grains, plant protein and unsaturated fats, and less red and processed meat, potatoes and sodium23.

For tracking metabolic health, a post Gokhan Can reshared lists the metabolic syndrome criteria, including HDL below 50 mg/dL and a waist above 35 inches (88 cm) in women, with insulin resistance driven by visceral fat24. Louis points out that in a Swedish study waist circumference beat BMI for obesity-related cancer risk in men but not women. His explanation is that women store more waist fat under the skin, while visceral fat is the dangerous kind25.

Hormone therapy: what the group's posts say

The timing idea and who is considered low risk

The core guidance Louis shared comes from the Cleveland Clinic and an American College of Cardiology working group review. Studies showed an increased risk of cardiovascular disease when HRT is started more than 10 years after menopause, and women who already have significant disease do worse. The review says hormone therapy "may be safe for healthy women aged < 60 years or within 10 years of menopause onset", but in advanced atherosclerosis it may destabilize plaque. Treatment is described as low-risk in women with recent menopause, normal weight and blood pressure, who are physically active and have a 10-year ASCVD risk below 5%. High-risk women with established disease (10-year risk above 10%) should not take HRT or bioidentical HRT (BHRT), nor should women with breast cancer1.

Louis shared a post by Hussein Yassine, who reviewed a case with Howard Hodis, a researcher on how the timing of hormone therapy relative to menopause may decide whether it helps or harms the vessels. The post covers the evidence on HRT and cardiovascular disease, "both positive and negative"4.

The Israeli observational study and a critique

An observational Israeli study of more than 80,000 women aged 50 or older (2000-2022) reported that HRT use was associated with several cancers. HRT offered some cardiovascular benefit when started at 50-65 but raised stroke and cancer risks, and starting at 65 or older significantly raised cancer and cerebrovascular risk26.

Louis then shared Dr Brian Lawenda's critique. The reported increases were far larger in women starting at 50-65 (cancer up 749%, stroke up 1,569%, ischemic heart disease up 817%) than in women starting after 65 (up 122%, 170% and 139%). Lawenda calls this implausible, saying it conflicts with physiology and prior evidence, and argues one observational study should not override decades of better evidence27. Note that these two posts reach opposite emphases: one presents the findings, the other questions them.

Breast cancer

Louis says that, based on randomized trials and prospective cohorts, systemic HRT of any kind is not recommended for women with a history of breast cancer. The quoted Breast Cancer Research Foundation text says a 2021 review found it significantly increased recurrence, especially in hormone receptor-positive disease, and a smaller trial was ended because of unacceptable risk2.

Brain health and dementia

Posts on the brain are cautious:

  • A shared critique of a study of about 183,000 women said those on hormone therapy had about 10% lower dementia diagnosis, but the effect was mostly absent in the roughly three-quarters with natural menopause and held only in those with surgically removed ovaries. A meta-analysis of 10 studies in over a million women found no reliable effect either way5.
  • Louis summarizes that there is currently no strong randomized evidence that HRT reduces dementia risk, and that APOE4 carriers who already have mild cognitive impairment or dementia may face specific risks. HRT's best-supported indications are bone protection and symptom relief4.
  • In a cohort of 2,766 women followed up to 25 years, each standard deviation increase in the blood marker p-tau217 tripled dementia risk (7-fold in the top versus bottom quartile). Women with elevated p-tau217 were at even higher risk if on estrogen plus progestin28.
The shared infographic on the 183,000-woman study (Squires et al., 2026): the 10% lower dementia risk on hormone therapy came from women with surgical menopause, with no clear effect in the roughly three in four women with natural menopause.
The shared infographic on the 183,000-woman study (Squires et al., 2026): the 10% lower dementia risk on hormone therapy came from women with surgical menopause, with no clear effect in the roughly three in four women with natural menopause.5

A separate 2025 lipidomics study of 841 adults found women with Alzheimer's had lower omega-3-rich blood lipids, which men did not. The proposed mechanism is that after menopause estrogen no longer boosts the enzyme FADS2 that helps make DHA. The post also cites a review of 58 trials suggesting 1,000-2,500 mg a day of EPA plus DHA as the cognitive "sweet spot"29. This is a cross-sectional study, so cause and effect are not shown.

Muscle

A 2026 meta-analysis of randomized trials (126 studies, 4,019 women) found premenopausal and postmenopausal women gained strength at virtually identical rates (standardised mean differences of 1.50 and 1.46)9. Louis adds that a 2019 JAMA Network Open meta-analysis found HRT alone does not add muscle without resistance training9.

Bone health after menopause

Bone loss accelerates after menopause because of declining estrogen, increasing osteoporosis and fracture risk30. Gokhan Can's checklist for osteopenia and osteoporosis puts weight-bearing exercise first, then discussing hormones with an endocrinologist, then eating 5-10 prunes a day, then having labs reviewed. He warns against starting calcium without medical advice because of heart risk, and considers bisphosphonates if nothing else helps31. These are his personal views.

  • Prunes. The Prune Study randomized 235 postmenopausal women (mean age about 62) to no prunes, 50 g or 100 g a day for 12 months. The 50 g group lost significantly less total hip bone density than controls, while 100 g added no benefit and had lower adherence830. An earlier summary reported better bone density maintenance when prunes were combined with calcium and vitamin D than with supplements alone32.
  • Zoledronate. In a 10-year NEJM trial of 1,054 women aged 50-60 with normal-to-low-normal bone density, new vertebral fractures occurred in 6.3% (two infusions) and 6.6% (one infusion) versus 11.1% on placebo; the relative risk for two doses versus placebo was 0.56 (95% CI 0.34-0.92)33.
  • Bisphosphonates more broadly. Gokhan's review reports alendronate cut vertebral and non-vertebral fractures by about 50% in women with prior vertebral fractures, and yearly zoledronic acid cut vertebral fractures 70% and hip fractures 40%. For the heart, a 2016 meta-analysis of 61 trials found reduced arterial calcification but no effect on cardiovascular events (RR 1.03), and a 2019 meta-analysis of 38 trials found no association with overall mortality (RR 0.98)34.
Zoledronate infusions nearly halved new spine fracturesWomen with a new vertebral fracture over 10 years, NEJM trial of 1,054 women aged 50–60 without osteoporosis
Two infusions6.3%
One infusion6.6%
Placebo11.1%
Two doses versus placebo: relative risk 0.56 (95% CI 0.34–0.92). Source: 33
Show data
Women with a new vertebral fracture (%)
Two infusions6.3%
One infusion6.6%
Placebo11.1%

Heart-protective measures that work in women

  • Statins. Louis rebutted the claim that statins are less effective in women. In the Cholesterol Treatment Trialists' meta-analysis of 27 randomized trials (about 174,000 participants), per 1 mmol/L LDL reduction major vascular events fell by rate ratio 0.84 in women and 0.78 in men (heterogeneity p=0.33), and all-cause mortality by 0.91 versus 0.90. There was no adverse effect on cancer incidence, and trials averaged only 4.9 years7.
  • Life's Essential 8. In UK Biobank, close adherence to the American Heart Association's eight health behaviours and measures for about 10 years was linked to 66% lower coronary heart disease risk, with larger benefits in women, younger adults and those with low genetic risk35.
  • Nuts and diet pattern. Louis shares evidence that nut intake correlates with 30-50% lower cardiovascular risk in cohorts including the Iowa Women's Health Study and Nurses' Health Study, and that in PREDIMED (7,216 people) the nut group halved stroke incidence36.
  • Coffee. Harvard's summary quoted by Louis notes that among 83,076 women in the Nurses' Health Study, 4 or more cups a day was associated with 20% lower stroke risk, and 2-3 cups a day with 21% lower heart disease risk in another cohort of 37,514 women, all observational37. Women who drank 1-3 cups of caffeinated coffee in their 50s were also more likely to age healthily38.
  • Black cumin. In a trial in postmenopausal women, about 1 g a day of black cumin powder lowered LDL by 27% in two months compared with placebo, and levels crept back a month after stopping3940. This is a small trial and not a replacement for medical therapy.
  • Tea and milk. In a 2007 Berlin trial in 16 healthy postmenopausal women, black tea improved flow-mediated dilation but adding skimmed milk (about a tenth of the cup) erased the benefit41.
Statins cut events about as much in women as in menRate ratio per 1 mmol/L LDL reduction, Cholesterol Treatment Trialists' meta-analysis of 27 randomized trials (about 174,000 people)
Major vascular events, women0.84
Major vascular events, men0.78
All-cause mortality, women0.91
All-cause mortality, men0.90
The difference between women and men in major vascular events was not significant (heterogeneity p = 0.33). Trials averaged 4.9 years. Source: 7
Show data
Rate ratio (log scale)95% CI
Major vascular events, women0.84–
Major vascular events, men0.78–
All-cause mortality, women0.91–
All-cause mortality, men0.90–

Protein, frailty and women's needs

Stuart Phillips argues that the muscle-related benefit of protein caps at about 1.6 g per kg a day, and only in people doing resistance training42. In part 2, shared by Louis, Phillips argues the ceiling holds in older adults and that women's requirement to spare lean tissue while losing weight is likely lower43. A Nurses' Health Study analysis in older women linked plant, but not animal or dairy, protein to lower frailty44. In older women with sarcopenia doing 12 weeks of resistance band training, adding vitamin C (1,000 mg) plus vitamin E (335 mg) produced larger gains in muscle and strength with lower IL-645.

Other women's health topics

  • PCOS. In a 12-week trial of 30 obese women with polycystic ovary syndrome, only acarbose significantly lowered liver fat, triglycerides and free fatty acids, compared with metformin or a lower-calorie diet46.
  • Pregnancy. Two Harvard studies found metformin taken by men or by women trying to conceive was not linked to higher birth defect risk47.
  • Magnesium. A summary Gokhan shared gives an adult women's recommended intake of 310-320 mg a day (360 mg if pregnant) and notes that nearly 45% of the US population has inadequate intake48.

What this means for you

  • Know your numbers rather than relying on sex-based reassurance. Both the Women's Health Study biomarkers and the CAC data suggest low-risk labels can mislead1417.
  • If considering HRT, the group's admins recommend discussing timing and personal risk with your doctor. The posts point to starting within 10 years of menopause or under 60, avoiding it with established cardiovascular disease or breast cancer, and not expecting it to prevent dementia or add muscle1259.
  • Do not avoid statins on the grounds that they work less well in women; the pooled trial data show similar proportional benefit7.
  • Lift weights: strength gains after menopause match those before it9.
  • For bones, weight-bearing exercise, prunes (50 g a day in the trial) and a medical review are the group's first steps831.
  • Talk to your doctor before starting calcium supplements31.

Frequently asked questions

Does menopause raise heart disease risk?

Louis cites early menopause as a risk factor and links slower ovarian ageing with slower overall ageing2021. A study he shared reported faster plaque accumulation in postmenopausal women than in men of the same age22. The posts do not quantify a menopause-specific effect.

Is HRT safe for the heart?

For healthy women under 60 or within 10 years of menopause, guidance he shared says it can be reasonably safe, but it is not advised with established cardiovascular disease1. Observational data are conflicting and contested2627.

Can HRT prevent dementia?

Not on current randomized evidence, according to the posts45.

Do women need a different cholesterol approach?

Statin trial data show comparable proportional benefit in women and men7.

Can I rely on a zero calcium score?

Not if you have symptoms. Half of symptomatic patients with blockages in the Danish registry had a zero score1415.

The evidence behind this summary47 studies · 7 meta-analyses · 10 trials · 18 observational

The 48 group posts cited above discuss 47 studies and sources. Their mix of study designs shows how much rests on randomized trials and meta-analyses, which can show cause and effect, and how much on observational, lab or animal work, which mostly cannot.

Meta-analyses 7Randomized trials 10Observational studies 18Reviews & guidelines 5Other sources 7

Strongest evidence discussed

All 47 studies and sources
Sources from the group (48)
  1. Menopausal hormone therapy is fairly safe for low-risk women, risky with established CVD Louis Nervegna · Apr 17, 2025 · Facebook
  2. HRT is not recommended for women with a history of breast cancer, even bioidentical Louis Nervegna · Aug 18, 2025 · Facebook
  3. Sterilization and contraception extend lifespan 10-20% across 117 vertebrate species Louis Nervegna · Dec 25, 2025 · Facebook
  4. Hormone therapy has no proven dementia benefit and may add risk in APOE4 carriers with MCI Louis Nervegna · Mar 29, 2026 · Facebook
  5. Hormone therapy and dementia: benefit mostly vanished in naturally menopausal women Louis Nervegna · Sep 02, 2026 · Facebook
  6. Men develop cardiovascular disease about 7 years earlier than women, per JAHA Louis Nervegna · Feb 02, 2026 · Facebook
  7. Statins work as well in women as men: 27-trial CTT meta-analysis of 174,000 participants Louis Nervegna · Dec 19, 2023 · Facebook
  8. Prune Study: 50 g of prunes daily preserved hip bone density in postmenopausal women Louis Nervegna · Jan 06, 2026 · Facebook
  9. Pre- and postmenopausal women gain strength equally from resistance training Louis Nervegna · Apr 16, 2026 · Facebook
  10. REACT in NEJM: 57% of adults have atherosclerosis and age is the biggest risk factor Louis Nervegna · Aug 30, 2026 · Facebook
  11. Age raises CVD death risk about 19.5x from 65 to 85, far above diabetes or smoking Louis Nervegna · Dec 18, 2023 · Facebook
  12. Same CT plaque, lower MI risk in women than men in a 10,003-person Danish cohort Louis Nervegna · Aug 30, 2026 · Facebook
  13. Mayo Clinic: over half of heart attacks in women under 65 had nontraditional causes Louis Nervegna · Sep 28, 2025 · Facebook
  14. A zero CAC does not rule out plaque in symptomatic patients; 54% had CAC 0 in Denmark Louis Nervegna · Dec 22, 2023 · Facebook
  15. A zero CAC score does not rule out blockages: 54% of 23,759 symptomatic patients had CAC 0 Louis Nervegna · Jan 01, 2025 · Facebook
  16. Half of people with symptomatic blockages had a CAC score of zero in Danish registry Louis Nervegna · Oct 05, 2025 · Facebook
  17. NEJM: hs-CRP, LDL and Lp(a) each predicted 30-year CVD risk in women, best combined Louis Nervegna · Aug 31, 2024 · Facebook
  18. Hysterectomy before 50 linked to higher CVD risk in Nurses' Health Studies Louis Nervegna · May 18, 2025 · Facebook
  19. Uterine fibroids linked to over 80% higher long-term heart disease risk Louis Nervegna · Dec 17, 2025 · Facebook
  20. Ovarian aging may track lifespan; early menopause raises heart disease risk in women Louis Nervegna · Oct 14, 2025 · Facebook
  21. Slower ovarian aging tracks slower overall aging and lower CVD risk, argues Louis Louis Nervegna · Feb 04, 2026 · Facebook
  22. Post-menopausal women may build plaque faster than men; statins alone may not suffice Louis Nervegna · Apr 08, 2024 · Facebook
  23. Low-insulinemic and Planetary Health diets tied to less weight gain at menopause Louis Nervegna · Jun 13, 2026 · Facebook
  24. Metabolic health beyond the scale: waist-to-height ratio, TG/HDL and adiponectin Gokhan Can · Sep 17, 2025 · Facebook
  25. Waist size beats BMI for obesity-related cancer risk in men, likely via visceral fat Louis Nervegna · Mar 26, 2025 · Facebook
  26. Hormone therapy started after 65 linked to higher cancer and stroke risk in Israeli cohort Louis Nervegna · Mar 18, 2026 · Facebook
  27. Israeli HRT study's 749% higher cancer risk at ages 50-65 is implausible, says oncologist Louis Nervegna · Mar 19, 2026 · Facebook
  28. Plasma p-tau217 predicts dementia: 3x per SD, 7x top vs bottom quartile in 2,766 women Louis Nervegna · Apr 05, 2026 · Facebook
  29. Women with Alzheimer's show lower omega-3 lipids, unlike men, in an 841-adult study Louis Nervegna · Dec 17, 2025 · Facebook
  30. Eating 50 g of prunes daily for a year protected hip bone density in postmenopausal women Louis Nervegna · Dec 26, 2025 · Facebook
  31. How to deal with bone loss: exercise, hormones, prunes, labs and bisphosphonates Gokhan Can · Jan 02, 2025 · Facebook
  32. Prunes help maintain bone density in postmenopausal women, researcher says Gokhan Can · Oct 04, 2024 · Facebook
  33. One zoledronate infusion cut vertebral fractures about 44% over 10 years in women 50-60 Gokhan Can · Jan 18, 2025 · Facebook
  34. Bisphosphonates for bone loss: fracture reductions summarized Gokhan Can · Oct 13, 2024 · Facebook
  35. Following AHA Life's Essential 8 for ~10 years linked to 66% lower coronary heart disease Louis Nervegna · Jul 11, 2025 · Facebook
  36. Ornish program now allows nuts and seeds, citing 30-50% lower CVD risk and PREDIMED Louis Nervegna · Jul 25, 2024 · Facebook
  37. Coffee linked to 15-21% lower CVD risk and lower stroke risk in Harvard evidence summary Louis Nervegna · Dec 29, 2023 · Facebook
  38. Nurses' Health Study: 1-3 daily cups of coffee in midlife linked to healthier aging Louis Nervegna · Jun 02, 2025 · Facebook
  39. Black cumin meta-analyses show better lipids, BP and glucose; LDL fell 27% in one trial Louis Nervegna · Dec 08, 2025 · Facebook
  40. Black cumin powder (1 g/day) lowered LDL 27% in postmenopausal women in two months Louis Nervegna · Nov 07, 2026 · Facebook
  41. Black tea improved artery function in a Berlin trial, but adding milk erased the benefit Louis Nervegna · Oct 31, 2026 · Facebook
  42. Stuart Phillips preprint: muscle benefit of protein still caps at 1.6 g/kg Louis Nervegna · Oct 08, 2026 · Facebook
  43. Stuart Phillips: the 1.6 g/kg protein ceiling holds for older adults; women may need less Louis Nervegna · Mar 29, 2026 · Facebook
  44. Nurses' Health Study: plant but not animal protein linked to lower frailty in older women Louis Nervegna · Aug 31, 2024 · Facebook
  45. Vitamin C and E did not blunt resistance training gains in older women with sarcopenia Louis Nervegna · Sep 08, 2025 · Facebook
  46. Acarbose cut liver fat in a 12-week RCT in women with PCOS, unlike metformin or diet Louis Nervegna · Jan 05, 2026 · Facebook
  47. Two Harvard studies found no extra birth-defect risk with metformin in men or women Louis Nervegna · Aug 24, 2024 · Facebook
  48. Magnesium: intake targets, widespread inadequacy and health roles (FoundMyFitness summary) Gokhan Can · Mar 19, 2024 · Facebook

Keep exploring

Related research summaries

Topics and hashtags in this summary